Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) stock fell -1.05% on Friday to $4.70 against a previous-day closing price of $4.75. With 16.75 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.82 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $4.7900 whereas the lowest price it dropped to was $4.6000. The 52-week range on VNDA shows that it touched its highest point at $11.04 and its lowest point at $4.15 during that stretch. It currently has a 1-year price target of $7.00. Beta for the stock currently stands at 0.71.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of VNDA was up-trending over the past week, with a rise of 1.73%, but this was down by -18.69% over a month. Three-month performance dropped to -25.87% while six-month performance fell -26.22%. The stock lost -53.56% in the past year, while it has lost -36.40% so far this year. A look at the trailing 12-month EPS for VNDA yields 0.26 with Next year EPS estimates of -0.17. EPS is expected to grow by 36.10% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 18.30%.
Float and Shares Shorts:
At present, 57.45 million VNDA shares are outstanding with a float of 55.19 million shares on hand for trading. On Aug 30, 2023, short shares totaled 2.8 million, which was 4.87% higher than short shares on Jul 30, 2023. In addition to Dr. Mihael H. Polymeropoulos M.D. as the firm’s Founder, Pres, CEO & Chairman of The Board, Mr. Kevin Patrick Moran serves as its Sr. VP, CFO & Treasurer.
Through their ownership of 104.51% of VNDA’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 53.69% of VNDA, in contrast to 45.89% held by mutual funds. Shares owned by individuals account for 32.42%. As the largest shareholder in VNDA with 16.53% of the stake, BlackRock Fund Advisors holds 9,506,119 shares worth 9,506,119. A second-largest stockholder of VNDA, The Vanguard Group, Inc., holds 4,108,597 shares, controlling over 7.14% of the firm’s shares. SSgA Funds Management, Inc. is the third largest shareholder in VNDA, holding 4,080,636 shares or 7.10% stake. With a 7.10% stake in VNDA, the iShares Core S&P Small Cap ETF is the largest stakeholder. A total of 4,083,784 shares are owned by the mutual fund manager. The SPDR S&P Biotech ETF, which owns about 3.30% of VNDA stock, is the second-largest Mutual Fund holder. It holds 1,899,656 shares valued at 9.86 million. Vanguard Total Stock Market ETF holds 3.00% of the stake in VNDA, owning 1,722,130 shares worth 8.94 million.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Jun 29, 2023, VNDA reported revenue of $64.39M and operating income of $3.46M. The EBITDA in the recently reported quarter was $4.15M and diluted EPS was $0.05.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for VNDA since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With VNDA analysts setting a high price target of $7.00 and a low target of $7.00, the average target price over the next 12 months is $7.00. Based on these targets, VNDA could surge 48.94% to reach the target high and rise by 48.94% to reach the target low. Reaching the average price target will result in a growth of 48.94% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.
Summary of Insider Activity:
Insiders traded VNDA stock several times over the past three months with 0 Buys and 4 Sells. In these transactions, 0 shares were bought while 12,436 shares were sold. The number of buy transactions has increased to 14 while that of sell transactions has risen to 20 over the past year. The total number of shares bought during that period was 516,243 while 255,974 shares were sold.